Article
Glucagon/GLP-1 receptor co-agonist NNC9204-1177 reduced body weight in adults with overweight or obesity but was associated with safety issues
2022-06-03
Abstract excerpt
Glucagon/glucagon-like peptide-1 (GLP-1) receptor co-agonists may provide greater weight loss than agonists targeting the GLP-1 receptor alone. We report results from three phase 1 trials investigating the glucagon/GLP-1 receptor co-agonist NNC9204-1177 (NN1177) for once-weekly subcutaneous use in adults with overweight or obesity. Our focus was a 12–week multiple ascending dose (MAD), placebo-controlled, double-b...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- be415d36-c4c8-5aa8-be53-7fb30ab0341e
- DOI
- 10.1101/2022.06.02.22275920
